Skip to the answer

Eravacycline Injection

Eravacycline is an intravenous antibiotic used to treat complicated intra-abdominal infections in adults.

Brand name Xerava
Drug class Tetracycline-class Antibacterial
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Eravacycline Injection at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Xerava (eravacycline) is an IV antibiotic in the tetracycline family, on the U.S. market since about 2018, that treats complicated infections inside the belly in adults by blocking bacteria from making the proteins they need; it is kept for proven or strongly suspected infections, often drug-resistant ones, to protect its effectiveness. Most people tolerate it reasonably well, with nausea, vomiting, or a sore, red IV site the usual complaints. The key risks are serious allergic reactions and C. difficile diarrhea, a dangerous gut infection that can start weeks after the last dose, so report hives, trouble breathing, or persistent watery or bloody diarrhea right away.

Clinical pearls

  • Tell your care team about any past reaction to doxycycline, minocycline or another tetracycline, since that allergy rules Xerava out.
  • If you take warfarin or another blood thinner, expect closer clotting checks, because Xerava can strengthen its effect.
  • Rifampin and similar drugs that speed up liver breakdown can lower Xerava levels, so make sure the hospital team knows.
  • Avoid breastfeeding during treatment and for 4 days after the last dose.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asInjection
Earliest FDA record2018
Companies listing it with the FDA1
FDA label last updatedSep 22, 2025
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Eravacycline Injection, written from its FDA label.

What Eravacycline Injection is used for

▾

Eravacycline injection is an intravenous antibiotic approved for the following use:

  • Xerava (intravenous): Treatment of complicated intra-abdominal infections (cIAI) — serious bacterial infections inside the abdomen — in adults 18 years and older, caused by susceptible bacteria including E. coli, Klebsiella pneumoniae, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Bacteroides species, and several others
  • Xerava is not approved for complicated urinary tract infections (cUTI)
  • Xerava should only be used when a bacterial infection is proven or strongly suspected, to help prevent antibiotic resistance

How Eravacycline Injection works

▾

Eravacycline is a fluorocycline antibiotic — a newer member of the tetracycline family. It kills or stops the growth of bacteria by binding to the 30S ribosomal subunit, a small structure inside bacterial cells that acts like a protein-building machine. By latching onto this structure, eravacycline blocks bacteria from assembling the proteins they need to survive, grow, and multiply.

Eravacycline generally stops bacterial growth (bacteriostatic) rather than directly killing bacteria outright for gram-positive organisms like Staphylococcus aureus. It is active against a wide range of bacteria, including some that have developed resistance to other antibiotics.

Eravacycline Injection dosage

▾

Xerava is given only by intravenous (IV) infusion — directly into a vein — in a hospital or clinical setting. Each infusion runs over about 60 minutes and is given every 12 hours. A full course of treatment typically lasts 4 to 14 days, guided by how severe the infection is and how the patient responds.

  • Patients with severe liver disease may receive a modified dosing schedule starting on Day 2
  • If you are also taking a strong CYP3A inducer (like rifampin), your doctor may increase the dose to keep drug levels effective
  • No dose adjustment is needed for kidney disease

Dosing details from the FDA-approved label

From the Eravacycline Injection prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Adults with complicated intra-abdominal infections (cIAI) - recommended adult dosage
    • 1 mg/kg by intravenous infusion over approximately 60 minutes every 12 hours for a total duration of 4 to 14 days
    • Duration of therapy should be guided by the severity and location of infection and the patient's clinical response
  • Severe hepatic impairment (Child Pugh C)
    • 1 mg/kg every 12 hours on Day 1, then 1 mg/kg every 24 hours starting on Day 2 for a total duration of 4 to 14 days
    • No dosage adjustment is warranted in mild to moderate hepatic impairment (Child Pugh A and B)
  • Concomitant use of a strong CYP3A inducer
    • 1.5 mg/kg every 12 hours for a total duration of 4 to 14 days
    • No dosage adjustment is warranted with concomitant use of a weak or moderate CYP3A inducer
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Administer XERAVA for injection 1 mg/kg by intravenous infusion over approximately 60 minutes every 12 hours for a total duration of 4 to 14 days. ( 2.1 ) Severe Hepatic Impairment (Child Pugh C): 1 mg/kg XERAVA every 12 hours on Day 1, then 1 mg/kg every 24 hours starting on Day 2 for a total duration of 4 to 14 days. ( 2.2 ) Concomitant Use of a Strong Cytochrome P450 (CYP) Isoenzyme 3A Inducer: 1.5 mg/kg XERAVA every 12 hours for a total duration of 4 to 14 days. ( 2.3 ) See full prescribing information for the preparation of XERAVA. ( 2.4 ) 2.1 Recommended Adult Dosage The recommended dose regimen of XERAVA is 1 mg/kg every 12 hours. Administer intravenous infusions of XERAVA over approximately 60 minutes every 12 hours. The recommended duration of treatment with XERAVA for cIAI is 4 to 14 days. The duration of therapy should be guided by the severity and location of infection and the patient's clinical response. 2.2 Dosage Modifications in Patients with Hepatic Impairment In patients with severe hepatic impairment (Child Pugh C), administer XERAVA 1 mg/kg every 12 hours on Day 1 followed by XERAVA 1 mg/kg every 24 hours starting on Day 2 for a total duration of 4 to 14 days. No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B) [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )]. 2.3 Dosage Modifications in Patients with Concomitant Use of a Strong Cytochrome P450 (CYP) Isoenzyme 3A Inducer With concomitant use of a strong CYP3A inducer, administer XERAVA 1.5 mg/kg every 12 hours for a total duration of 4 to 14 days. No dosage adjustment is warranted in patients with concomitant use of a weak or moderate CYP3A inducer [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )]. 2.4 Preparation and Administration XERAVA is for intravenous infusion only. Each vial is for a single dose only. Preparation XERAVA is supplied as a sterile yellow to orange dry powder in a single-dose vial that must be reconstituted and further diluted prior to intravenous infusion as outlined below. XERAVA does not contain preservatives. Aseptic technique must be used for reconstitution and dilution as follows: Calculate the dose of XERAVA based on the patient weight (1 mg/kg actual body weight).

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Eravacycline Injection side effects

▾

The most common side effects reported with Xerava include:

Common side effects

  • Infusion site reactions (pain, redness, swelling, or phlebitis at the IV site)
  • Nausea
  • Vomiting
  • Diarrhea
  • Low blood pressure (hypotension)
  • Dizziness
  • Rash
  • Altered taste (dysgeusia)
  • Wound dehiscence (a surgical wound reopening)
  • Rash or excessive sweating

When to get medical help

  • Signs of a severe allergic reaction — hives, swelling of the face or throat, difficulty breathing, or feeling faint
  • Persistent or severe diarrhea (which may be watery or bloody) — this could be C. difficile-associated diarrhea, a serious gut infection
  • Signs of liver problems — unusual fatigue, yellowing of skin or eyes, dark urine
  • Signs of abnormal pancreas function — severe stomach pain, especially with nausea or vomiting
  • New or worsening shortness of breath or chest pain
  • If you are pregnant, any new concerns — this drug can affect fetal bone and tooth development

More serious reactions — including life-threatening allergic reactions, severe C. difficile diarrhea, or signs of liver or pancreas problems — require immediate medical attention. Tell your care team right away if anything feels off.

Eravacycline Injection warnings and precautions

▾
  • Serious allergic reactions: Life-threatening anaphylaxis has been reported with Xerava and other tetracyclines. Do not use Xerava if you are allergic to tetracycline antibiotics. Seek emergency help immediately for hives, throat swelling, or trouble breathing.
  • C. difficile-associated diarrhea (CDAD): Antibiotics can disturb the normal gut bacteria and allow C. difficile to overgrow, causing anything from mild diarrhea to a severe, life-threatening colon infection. This can occur even weeks after finishing treatment. Persistent or bloody diarrhea should be reported promptly.
  • Tooth staining and bone effects in children and fetuses: Tetracyclines — including eravacycline — can permanently yellow-gray-brown stain developing teeth and slow bone growth when used during the second or third trimester of pregnancy or in children under 8.
  • Tetracycline class reactions: Reactions seen with other tetracyclines — such as increased pressure inside the skull (pseudotumor cerebri), skin sensitivity to sunlight (photosensitivity), pancreatitis, and abnormal liver tests — may also occur with Xerava.
  • Overgrowth of resistant organisms: Like all antibiotics, Xerava can allow non-susceptible bacteria or fungi to grow. Inform your care team if you develop new or worsening signs of infection.

Eravacycline Injection interactions

▾

Eravacycline has a few important drug interactions to be aware of:

  • Rifampin and other strong CYP3A inducers — these drugs speed up the breakdown of eravacycline in the body, reducing its blood levels and potentially making it less effective. Your doctor may increase the Xerava dose if you are taking one of these medications.
  • Blood thinners (anticoagulants, such as warfarin) — tetracyclines can reduce the activity of clotting proteins in the blood, which may make anticoagulants work stronger. Your anticoagulant dose may need to be lowered while you're on Xerava.
  • Strong CYP3A inhibitors (such as itraconazole) — these can modestly increase eravacycline exposure, though no dose adjustment is currently specified in the label for this interaction.

Interactions listed in the FDA-approved label

From the Eravacycline Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A inducers: Concomitant use decreases the exposure of eravacycline, which may reduce the efficacy of XERAVA. Increase XERAVA dose in patients with concomitant use of a strong CYP3A inducer (1.5 mg/kg every 12 hours).
  • Anticoagulant drugs: Because tetracyclines have been shown to depress plasma prothrombin activity, patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Downward adjustment of anticoagulant dosage may be required.
Read the label’s full interactions text

7 DRUG INTERACTIONS Strong CYP 3A Inducers: Co-administration decreases the exposure of eravacycline; increase XERAVA dose with concomitant use. ( 2.3 , 7.1 , 12.3 ) Anticoagulant Drugs: Downward adjustment of anticoagulant dosage may be required. ( 7.2 ) 7.1 Effect of Other Drugs on XERAVA Strong CYP3A Inducers Concomitant use of strong CYP3A inducers decreases the exposure of eravacycline, which may reduce the efficacy of XERAVA [see Clinical Pharmacology ( 12.3 )] . Increase XERAVA dose in patients with concomitant use of a strong CYP3A inducer [see Dosage and Administration ( 2.3 )] . 7.2 Effect of XERAVA on other Drugs Anticoagulant Drugs Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿145 supplements and herbs with documented Eravacycline Injection interactions, ranked by severity Check Eravacycline Injection against a supplement or herb →

Before taking Eravacycline Injection

▾
  • Tetracycline allergy: Xerava is contraindicated if you have a known allergy to eravacycline, any tetracycline-class antibiotic, or any ingredient in Xerava.
  • Pregnancy: Xerava can permanently stain your baby's teeth and slow bone growth if used in the second or third trimester. Talk to your doctor immediately if you are or become pregnant.
  • Breastfeeding: Breastfeeding is not recommended during treatment or for 4 days after the last dose, due to the risk of tooth staining and bone effects in the infant.
  • Children under 8: Xerava is not recommended for children under 8 because of the risk to developing teeth and bones. Safety and effectiveness have not been established in any pediatric patients.
  • Severe liver disease (Child-Pugh Class C): The dosing schedule must be adjusted — tell your doctor if you have serious liver problems.
  • Kidney disease: No dose adjustment is needed, even for end-stage renal disease.
  • Older adults: No difference in safety or effectiveness was found in patients 65 and older in clinical trials. No dose adjustment is required based on age alone.
  • Males concerned about fertility: Animal studies suggest eravacycline may temporarily affect sperm; long-term effects on human male fertility have not been fully studied.

Eravacycline Injection overdose

▾

No overdose cases were reported in Xerava's clinical trials. If an overdose is suspected, Xerava should be stopped and the patient watched closely for side effects. Hemodialysis (kidney dialysis) is not expected to meaningfully remove eravacycline from the body.

What Eravacycline Injection does in the body

▾

Eravacycline's effectiveness is best predicted by how much total drug exposure occurs relative to the minimum amount needed to stop the bacteria from growing — a measure called AUC/MIC. At the recommended dose, eravacycline appears to reach the level of exposure where increasing the dose further would not meaningfully improve results. In a dedicated heart-rhythm study, Xerava at 1.5 times the maximum approved dose did not cause any clinically meaningful prolongation of the QTc interval (the heart's electrical recovery time), suggesting a low risk of drug-related heart rhythm effects at therapeutic doses.

How your body processes Eravacycline Injection

▾

Eravacycline is given by IV infusion over about 60 minutes. It distributes widely throughout the body — with a large volume of distribution of roughly 321 liters — meaning it spreads well into tissues. It is 79–90% bound to proteins in the blood and is broken down primarily by liver enzymes (CYP3A4 and FMO). About one-third of the drug is excreted in urine and nearly half in feces. The average elimination half-life is 20 hours, meaning it takes roughly 20 hours for the body to clear half of the drug. Drug levels build up by roughly 45% with twice-daily dosing, reaching a steady state over several days. Patients with severe liver disease have significantly higher drug exposure and require a dose adjustment, while kidney disease — even severe — does not meaningfully change drug exposure.

How to store Eravacycline Injection

▾

stored at 2°C to 8°C (36°F to 46°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

145

Supplements & herbs that interact with Eravacycline Injection

145 supplements and herbal products have documented interactions with Eravacycline Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 3
  • Moderate · 109
  • Minor · 33
GRAPEFRUIT Major OLEANDER Major ST. JOHN'S WORT Major ACACIA RIGIDULA Moderate ADRAFINIL Moderate AFRICAN WILD POTATO Moderate AMERICAN ELDER Moderate ASTAXANTHIN Moderate +137 more
Every supplement checked against Eravacycline Injection — ranked by severity The full interaction hub: 3 major · 109 moderate · 33 minor · every one linked to its full report. Check Eravacycline Injection against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Eravacycline Injection: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Eravacycline Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is Xerava used for?

▾
Xerava is an antibiotic used to treat serious bacterial infections inside the abdomen — things like an infected appendix, perforated bowel, or other complicated abdominal infections. It's given in a hospital or clinical setting through an IV, and it works against a range of bacteria that commonly cause these infections. It's not used for urinary tract infections.

How is Xerava given, and how long will I need it?

▾
Xerava is given as an IV infusion — a slow drip into a vein — over about 60 minutes, usually every 12 hours. Your treatment will typically last somewhere between 4 and 14 days, depending on how serious your infection is and how well you're responding. Your care team will monitor you closely and decide when it's safe to stop.

What side effects should I watch out for?

▾
The most common side effects are nausea, vomiting, and reactions at the IV site like pain or redness. These are usually manageable. The more important things to watch for are signs of a severe allergic reaction — like swelling of the face or throat, trouble breathing, or a rash that spreads quickly — or persistent diarrhea that starts during or after treatment, which could be a serious gut infection called C. difficile. Let your care team know right away if any of these happen.

Can I take Xerava if I'm pregnant or breastfeeding?

▾
This is really important to discuss with your doctor. Xerava, like other tetracycline antibiotics, can permanently discolor your baby's developing teeth and slow their bone growth if you're in your second or third trimester of pregnancy. If you're breastfeeding, you're advised not to breastfeed during treatment and for 4 days after your last dose, because of those same risks to the baby. Make sure your care team knows your situation.

Are there any medications I should tell my doctor about before starting Xerava?

▾
Yes — definitely mention all the medications you're taking. The two most important interactions are with rifampin (an antibiotic sometimes used for tuberculosis), which can reduce how much Xerava stays in your system, and blood thinners like warfarin, which may work stronger than usual when combined with Xerava. Your doctor may need to adjust doses on either end to keep you safe.

Is Xerava safe if I have kidney or liver disease?

▾
If you have kidney disease — even severe kidney disease — no dose change is needed for Xerava. Liver disease is a different story. Mild to moderate liver disease doesn't require a change either, but if you have severe liver disease, your doctor will adjust your dosing schedule to make sure you don't get too much of the drug. Make sure your care team knows your full medical history before you start.

Is Eravacycline Injection available over the counter?

▾
No. Eravacycline Injection is a prescription medicine: every Eravacycline Injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Eravacycline Injection first available?

▾
The earliest FDA record we hold for Eravacycline Injection is from 2018: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Eravacycline Injection was first used.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Eravacycline Injection on HelloPharmacist

📊Eravacycline Injection supplement interactions145 checked — ranked by severity 🌿Drug & Supplement CheckerEravacycline Injection vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Eravacycline Injection NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Eravacycline Injection Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Eravacycline Injection forms and strengths (how it comes)

Eravacycline Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Eravacycline Injection inactive ingredients by manufacturer.

Injection

By injection · Into a vein
Brands Xerava
How this form is used
What it may be used for
  • Xerava is used to treat complicated intra-abdominal infections (serious infections inside the abdomen) in adults 18 and older
  • Xerava targets specific bacteria including E. coli, Klebsiella pneumoniae, Enterococcus, Staphylococcus aureus, Bacteroides species, and others confirmed or suspected to be causing the infection
  • Xerava is not approved for complicated urinary tract infections
Important instructions
  • Xerava is given as an IV infusion over approximately 60 minutes, typically every 12 hours
  • Xerava must be reconstituted and diluted before infusion — it is not for direct injection and is prepared fresh by healthcare staff
  • Xerava should not be mixed with other drugs in the same IV line; the line should be flushed with normal saline before and after infusion
  • Xerava treatment typically lasts 4 to 14 days depending on infection severity and patient response — follow your care team's guidance
Available strengths 3 strengths
50 mg 100 mg 100 mg/10 mL
10 FDA-listed product records ⓘ

Eravacycline Injection on the U.S. market: products, makers and brands

How Eravacycline Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

1 company lists 2 Eravacycline Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2018. Brand names on the directory include Xerava; the rest are generics.

1
Dose forms ⓘ
1
Labelers (makers, repackagers, distributors)
1
Brand names
2
FDA-listed product records ⓘ
2018
Earliest FDA record ⓘ

How widely Eravacycline Injection is used (Medicaid data)

A general measure of how commonly Eravacycline Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Eravacycline Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

277
Medicaid prescriptions filled (Q1–Q4 2025)
$97,341 gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Eravacycline Injection prescribed? Of the 1,601 medications we measure, Eravacycline Injection ranks #1,430 by Medicaid prescriptions — more than 11% of them.

Where Eravacycline Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,430 of 1,601
#1,425 Lopinavir and Ritonavi... 282 Rx #1,426 Methyldopa 282 Rx #1,427 Methyl Salicylate 282 Rx #1,428 Methamphetamine 281 Rx #1,429 Adagrasib 278 Rx #1,430 Eravacycline Injection 277 Rx #1,431 Brodalumab Injection 273 Rx #1,432 Elotuzumab Injection 269 Rx #1,433 Bexarotene 266 Rx #1,434 Dexrazoxane Injection 265 Rx #1,435 Sotorasib 265 Rx

Utilization by Eravacycline Injection product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 100 mg injection is the most-dispensed Eravacycline Injection product — about 52% of these Medicaid prescriptions.

eravacycline 100 MG Injection Most dispensed

144 Medicaid prescriptions (Q1–Q4 2025) 52% of Eravacycline Injection prescriptions shown $72,385 gross reimbursement (before rebates) ≈ $503 per prescription (gross)

Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2374556

eravacycline 50 MG Injection

133 Medicaid prescriptions (Q1–Q4 2025) 48% of Eravacycline Injection prescriptions shown $24,957 gross reimbursement (before rebates) ≈ $188 per prescription (gross)

Summed across the 1 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2055911

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Eravacycline Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 7 listed Eravacycline Injection NDCs with Medicaid activity.

Compare Eravacycline Injection products

A representative set of FDA-listed product records for Eravacycline Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
50 mg Intravenous Tetraphase Pharmaceuticals, Inc. NDA View NDC →
100 mg Intravenous Tetraphase Pharmaceuticals, Inc. NDA View NDC →

Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Eravacycline Injection NDCs →

Eravacycline Injection recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Eravacycline recalls since July 2021.

✅No Eravacycline recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Eravacycline Injection RxCUI 2055906 1 dose form · 2 strengths
  1. Dose form (SCDF) Injection RxCUI 2055910 In current FDA listings
    Clinical drug / strength (SCD) 50 MG RxCUI 2055911 100 MG RxCUI 2374556

Look up RxCUI 2055906 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Eravacycline Injection brand names

Eravacycline Injection is sold under one brand name in the FDA directory — Xerava. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Xerava

Who makes Eravacycline Injection: manufacturers and labelers

One company lists Eravacycline Injection products with the FDA. By number of product records, the largest are Tetraphase Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Tetraphase Pharmaceuticals, Inc. 2

Eravacycline Injection drug class (RxNorm)

Eravacycline Injection belongs to the Tetracycline-class Antibacterial class.

Pharmacologic class Tetracycline-class Antibacterial
Drug family (ATC) Tetracyclines

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Eravacycline Injection page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Sep 22, 2025
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Eravacycline Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Eravacycline Injection after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
1
Finished products in the current FDA directory
2
Companies listing them (makers, repackagers, distributors)
1
FDA labeler codes behind them ⓘ
1
Linked representative label ⓘ
Tetraphase Pharmaceuticals, Inc.
Linked label effective
Sep 22, 2025
Composite sections available
22
Linked SPL Set ID
a4b188d4-f467-470c-ad7b-25ffbdd8862a
Linked SPL Document ID
77aceb1e-e4ae-4416-8f32-7ebe72348488
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Tetraphase Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →